



EXPRESS MAIL NO.: EV 452 772 615 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kensil

Confirmation No.: 7453

Application No.: 09/369,941

Group Art Unit: 1632

Filed: August 6, 1999

Examiner: Wilson, Michael C.

For: COMPOSITIONS OF CPG AND
SAPONIN ADJUVANTS AND USES
THEREOF

Attorney Docket No.: 8449-156-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97 & §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby direct the Examiner's attention to the references D01-D20, E01-E06 and F01-F30 listed on the attached revised form PTO 1449. A copy of each of references D01-D20, E01-E06 and F01-F30 is provided herewith.

While not to be construed as indicating that the Examiner should not review and consider all of the listed references, the Examiner's attention is particularly directed to U.S. Patent No. 6,544,518 (Ref. D13; see, e.g., claim 1), U.S. Patent Application Publication No. 2003/0161834 (Ref. D19; see, e.g., claim 1), U.S. Patent Application Publication No. 2002/0164341 (Ref. D16; see, e.g., claim 1), and U.S. Patent Application Publication No. 2003/0224010 (Ref. D18).

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants submit herewith a "revised form PTO 1449"

entitled "List of References Cited" instead of an "Information Disclosure Citation in an Application".

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(4), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a request for continued examination under § 1.114, the fee required to be filed with the accompanying Information Disclosure Statement has been estimated to be \$0.00. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 503013. A copy of this sheet is enclosed.

Respectfully submitted,

Date April 26, 2004

 32,605
Adriane M. Antler (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

8449-156-999

APPLICATION NO

09/369,941

APPLICANT

Kensil C.

FILING DATE

August 6, 1999

GROUP

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D01	4,469,863	09/04/84	Ts'o et al.		
	D02	4,522,811	6/11/85	Eppstein et al.		
	D03	5,023,243	6/11/91	Tullis		
	D04	5,057,540	10/15/91	Kensil et al.		
	D05	5,273,965	12/28/93	Kensil et al.		
	D06	5,352,449	10/4/94	Beltz et al.		
	D07	5,443,829	8/22/95	Kensil et al.		
	D08	5,583,112	12/10/96	Kensil et al.		
	D09	5,650,398	7/22/97	Kensil et al.		
	D10	5,977,081	11/2/99	Marciani		
	D11	6,231,859	5/15/01	Kensil		
	D12	6,524,584	2/25/03	Kensil		
	D13	6,544,518	4/8/03	Friede et al.		
	D14	6,558,670	5/6/03	Friede et al.		
	D15	6,645,495	11/11/03	Kensil et al.		
	D16	2002/0164341	11/7/02	Davis et al.		
	D17	2003/0091599	5/15/03	Davis et al.		
	D18	2003/0224010	12/4/03	Davis et al.		
	D19	2003/0161834	4/28/03	Friede et al.		
	D20	09/760,506		Kensil et al.		01/12/01

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	E01	WO 02/32450	4/25/02	PCT		
	E02	WO 98/37919	9/3/98	PCT		
	E03	WO 95/26204	10/5/95	PCT		
	E04	WO 98/40100	9/17/98	PCT		
	E05	BE 9908885	4/19/99	Belgium		
	E06	EP 1005368	3/10/98	Europe		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

F01	Agrawal et al., 1988, Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A. 85(19):7079-7083.
F02	Agrawal S. 1992, Antisense oligonucleotides as antiviral agents. Trends Biotechnol. 10(5):152-158
F03	Beaucage et al., 1981, Deoxynucleotide phosphoramidites - A new class of key intermediates for deoxypolynucleotide synthesis. Tet. Let. 22:1859-1862

	F04	Boggs et al., 1997, Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 7(5):461-471
	F05	Campbell & Peerbaye, 1992, Saponin. <i>Res. Immuno.</i> 143:526-530
	F06	Carson et al., 1997, Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. <i>J Exp Med.</i> 186(10):1621-1622
	F07	Chavali & Campbell, 1987, Immunomodulatory Effects of Orally-Administered Saponins and Nonspecific Resistance Against Rabies Infection. <i>Int. Archs. Allergy Appl. Immun.</i> 84:129-134
	F08	Chavali et al., 1988, Immunopotentiality by Orally-Administered <i>Quillaja</i> Saponins : Effects in Mice Vaccinated Intraperitoneally Against Rabies. <i>Clin. Exp. Immunol.</i> 74:339-343
	F09	Chavali et al., 1987, An <i>In Vitro</i> Study of Immunomodulatory Effects of Some Saponins. <i>Int. J. Immunopharmac.</i> 9(6):675-683
	F10	Dalsgaard, K. 1978, A study of the isolation and characterization of the saponin <i>quil a</i> . <i>Acta Veterinaria Scandinavica</i> 69:1-40
	F11	Elkins et al., 1999, Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. <i>J Immunol.</i> 162(4):2291-2298
	F12	Fröhler B, 1986, Deoxynucleoside H-Phosphonate diester intermediates in the synthesis of internucleotide phosphate analogues. <i>Tet. Let.</i> 27:5575
	F13	Fröhler et al., 1986, Synthesis of DNA via deoxynucleoside H-phosphonate intermediates. <i>Nucleic Acids Res.</i> 14(13):5399-5407
	F14	Gaffney et al., 1988, Large-scale oligonucleotide synthesis by the H-Phosphonate method. <i>Tet. Let.</i> 29:2619-2622
	F15	Garegg et al., 1986, Nucleoside H-phosphonates III. Chemical synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach. <i>Tet. Let.</i> 27:4051-4054
	F16	Garegg et al., 1986, Nucleoside H-phosphonates IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. <i>Tet. Let.</i> 27:4055-4058
	F17	Goodchild, J. 1990, Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. <i>Bioconjugate Chem.</i> 1:165
	F18	Higuchi et al. Structure of desacylsaponins obtained from the bark of <i>quillaja saponaria</i> . <i>Phytochemistry</i> 26:229-235
	F19	Kensil et al., 1992, Structure/Function relationship in adjuvants from <i>Quillaja saponaria</i> Molina. <i>Vaccine</i> 92 (Cold Spring Harbor Laboratory Press) pp. 35-40.:
	F20	Kim et al., 2001, Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. <i>Vaccine.</i> 19(4-5):530-537
	F21	Kirkby et al., Effects of anticholinesterase drugs tacrine and E2020, the 5-HT3 antagonist ondansetron, and the H3 antagonist thioperamide, in models of cognition and cholinergic function. <i>Behav Pharmacol.</i> 1996 Nov;7(6):513-525.
	F22	Klinman et al., 1996, CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci U S A.</i> 93(7):2879-2883
	F23	Krieg et al., 1996, Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev.</i> 6(2):133-139
	F24	Krieg et al., 1998, CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>Listeria monocytogenes</i> challenge. <i>J Immunol.</i> 161(5):2428-2434
	F25	Lipkin, 1995, "Vegemania: Scientists Tout the Heath Benefits of Saponins", <i>Science News</i> 148:392-393
	F26	Maharaj et al., 1986, Immune Responses of Mice to Inactivated Rabies Vaccine Administered Orally: Potentiation by <i>Quillaja</i> Saponin. <i>Can. J. Microbiol.</i> 32:414-420
	F27	Marciani et al., 1991, Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. <i>Vaccine.</i> 9(2):89-96
	F28	Newman et al., 1992, Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. <i>J Immunol.</i> 148(8):2357-2362
	F29	Rao & Sung, 1995, Saponins as Anticarcinogens. <i>J. Nutr.</i> 125:717S-724S,
	F30	Uhlmann et al., Antisense oligonucleotides: A new therapeutic principle. <i>Chem. Rev.</i> 9:544-584

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.